MARKET

PBYI

PBYI

Puma Biotechnology Inc
NASDAQ
3.010
-0.030
-0.99%
Closed 16:05 05/13 EDT
OPEN
3.110
PREV CLOSE
3.040
HIGH
3.110
LOW
2.930
VOLUME
310.75K
TURNOVER
--
52 WEEK HIGH
5.20
52 WEEK LOW
2.225
MARKET CAP
149.41M
P/E (TTM)
3.907
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PBYI last week (0505-0509)?
Weekly Report · 1d ago
Puma Biotechnology’s Earnings Call: A Mixed Bag
TipRanks · 4d ago
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
NASDAQ · 4d ago
Puma Biotechnology Terminates Chief Commercial Officer
TipRanks · 4d ago
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts
Seeking Alpha · 4d ago
PUMA BIOTECHNOLOGY INC - ON MAY 8 TERMINATES CHIEF COMMERCIAL OFFICER JEFF J. LUDWIG - SEC FILING
Reuters · 4d ago
Barclays Reaffirms Their Sell Rating on Puma Biotechnology (PBYI)
TipRanks · 4d ago
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Barchart · 4d ago
More
About PBYI
More
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Recently
Symbol
Price
%Change

Webull offers Puma Biotechnology Inc stock information, including NASDAQ: PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.